Publication Name	World Journal of Gastroenterology
Manuscript ID	84994
Country	Italy

Received	2023-06-07 19:02
Peer-Review Started	2023-06-07 19:03
To Make the First Decision
Return for Revision	2023-07-07 09:04
Revised	2023-07-21 19:57
Second Decision	2023-07-26 02:55
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2023-07-27 00:39
Articles in Press	2023-07-27 00:39
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2023-09-27 08:26
Publish the Manuscript Online	2023-10-12 10:39

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Case Report
Article Title	Dose escalation of adalimumab as a strategy to overcome anti-drug antibodies: A case report of infantile-onset inflammatory bowel disease
Manuscript Source	Unsolicited Manuscript
All Author List	Silvana Ancona, Sara Signa, Chiara Longo, Giuliana Cangemi, Roberta Carfora, Enrico Drago, Alessandro La Rosa, Marco Crocco, Andrea Chiaro, Paolo Gandullia and Serena Arrigo
Funding Agency and Grant Number
Corresponding Author	Serena Arrigo, MD, Staff Physician, Pediatric Gastroenterology and Endoscopy Unit, IRCCS Istituto Giannina Gaslini, 5 Via Gerolamo Gaslini, Genova 16147, Italy. serenaarrigo@gaslini.org
Key Words	Infantile-onset inflammatory bowel disease; Adalimumab; Loss of response; Dose escalation; Anti-drug antibodies; Case report
Core Tip	Infantile-onset inflammatory bowel disease (IBD) frequently has a more severe course and a greater resistance to standard therapy than IBD in older children. Anti-tumor necrosis factor agents often lead to the production of anti-drug antibodies, resulting in loss of clinical response and disease progression. For this reason, the early detection of anti-drug antibodies is important, which may be possible with therapeutic drug monitoring. To date, commonly used strategies to overcome anti-drug antibodies are switching drugs or adding an immunomodulator, but a better option may be dose escalation.
Publish Date	2023-10-12 10:39
Citation	Ancona S, Signa S, Longo C, Cangemi G, Carfora R, Drago E, La Rosa A, Crocco M, Chiaro A, Gandullia P, Arrigo S. Dose escalation of adalimumab as a strategy to overcome anti-drug antibodies: A case report of infantile-onset inflammatory bowel disease. World J Gastroenterol 2023; 29(38): 5428-5434
URL	https://www.wjgnet.com/1007-9327/full/v29/i38/5428.htm
DOI	https://dx.doi.org/10.3748/wjg.v29.i38.5428

Full Article (PDF)	WJG-29-5428-with-cover.pdf
Full Article (Word)	WJG-29-5428.docx
Manuscript File	84994_Auto_Edited-JLW.docx
Answering Reviewers	84994-Answering reviewers.pdf
Audio Core Tip	84994-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	84994-Conflict-of-interest statement.pdf
Copyright License Agreement	84994-Copyright license agreement.pdf
Signed Consent for Treatment Form(s) or Document(s)	84994-Informed consent statement.pdf
Non-Native Speakers of English Editing Certificate	84994-Language certificate.pdf
Peer-review Report	84994-Peer-review(s).pdf
Scientific Misconduct Check	84994-Bing-Chen YL-2.png
Scientific Editor Work List	84994-Scientific editor work list.pdf